Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JXX.0000000000000977 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy.
Breast Cancer Res Treat
December 2024
Medidata AI, Medidata Solutions, a Dassault Systèmes Company, 350 Hudson Street, New York, NY, 10014, USA.
The therapeutic importance of subsetting patients with HER2-negative breast cancer according to their tumors' cellular HER2 expression (e.g., HER2-low vs.
View Article and Find Full Text PDFShared Accountability Shaping the Destinies of Individual and Groups of Nonhuman Primates.
Vet Sci
October 2024
California National Primate Research Center, University of California, Davis, CA 95616, USA.
At the California National Primate Research Center (CNPRC), the preferred housing for rhesus macaques involves maintaining them in complex social groups outdoors, primarily for breeding purposes. This functionally appropriate environment promotes effective coping through the expression of species-typical behaviors and important aspects of species-typical social structure, thus enabling normal animal development, higher reproductive success, and the production of high-quality biological models. Despite the benefits, social housing introduces challenges like trauma from aggressive interactions.
View Article and Find Full Text PDFTrastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Nat Med
December 2024
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Article Synopsis
- The DESTINY-Breast12 study is the largest prospective trial examining the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer, including those with brain metastases (BMs).
- In this study, T-DXd showed promising results, with a 12-month progression-free survival (PFS) of 61.6% for patients with BMs and an objective response rate (ORR) of 62.7% for those without BMs.
- Adverse events were observed in both cohorts, with 51% of patients with BMs and 49% of those without experiencing grade 3 or higher side effects, indicating the need for careful monitoring
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.
Adv Ther
November 2024
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Article Synopsis
- The DESTINY-PanTumor02 study investigated trastuzumab deruxtecan (T-DXd) for treating HER2-expressing solid tumors in patients who had prior treatment, focusing on IHC 3+ and 2+ tumors across seven cancer types.
- Results showed a higher objective response rate (ORR) in patients with IHC 3+ tumors (51.4%) compared to those with IHC 2+ tumors (26.5%), with median durations of response of 14.2 months and 9.8 months, respectively.
- The study concluded that T-DXd provides significant clinical benefit, especially for patients with HER2 IHC 3+ tumors, reinforcing its therapeutic potential
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
Lancet Oncol
September 2024
Department for the Promotion of Drug and Diagnostic Development and Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Background: Trastuzumab deruxtecan has shown encouraging activity in patients with treatment-refractory HER2-positive, RAS wild-type and BRAF wild-type metastatic colorectal cancer. Dose optimisation and further antitumour assessments in patients with RAS mutations and those with previous anti-HER2 therapy are warranted. We aimed to evaluate two doses of trastuzumab deruxtecan (5·4 mg/kg and 6·4 mg/kg) to establish the recommended dose in patients with pretreated HER2-positive, RAS wild-type or mutant metastatic colorectal cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!